Back to Search Start Over

Better glycaemic control with BioChaperone glargine lispro co-formulation than with insulin lispro Mix25 or separate glargine and lispro administrations after a test meal in people with type 2 diabetes.

Authors :
Meiffren G
Herbrand T
Anastassiadis E
Klein O
DeVries JH
Heise T
Alluis B
Mégret C
Gaudier M
Soula O
Plum-Mörschel L
Source :
Diabetes, obesity & metabolism [Diabetes Obes Metab] 2019 Jul; Vol. 21 (7), pp. 1570-1575. Date of Electronic Publication: 2019 Apr 08.
Publication Year :
2019

Abstract

Because of its physico-chemical properties, insulin glargine is usually not mixable with rapid insulins. BioChaperone BC147 is a polyanionic amphiphilic polymer, solubilizing insulin glargine at neutral pH, and thus enabling stable glargine formulation with fast-acting insulin lispro (BioChaperone glargine lispro co-formulation [BC Combo]). We investigated pharmacokinetic (PK) endpoints and postprandial glucose (PPG) control after administration of BC Combo (75% insulin glargine, 25% insulin lispro), insulin lispro Mix25 (LMix) and separate injections of insulins glargine (75% total dose) and lispro (25% total dose [G + L]) immediately before ingestion of a mixed meal in people with type 2 diabetes mellitus (T2DM), using a randomized, double-blind, double-dummy crossover study design. Participants received individualized bolus doses (mean 0.62 U/kg) of BC Combo, LMix or G + L, together with a solid mixed meal (610 kcal, 50% carbohydrate, 30% fat, 20% protein). Insulin dosages were kept constant for each study day. Thirty-nine participants with T2DM (mean ± SD age and glycated haemoglobin 60.8 ± 7.5 years and  64 ± 6 mmol/mol, respectively) were randomized. BC Combo improved the predefined primary endpoint, early PPG control, compared to LMix (incremental area under the blood glucose concentration-time curve from 0 to 2 hours after the meal [ΔAUC <subscript>BG,0-2h</subscript> ] reduction of 18%; P = 0.0009) and G + L (ΔAUC <subscript>BG,0-2h</subscript> reduction of 10%; P = 0.0450). The number of mealtime hypoglycaemic episodes per participant was lower with BC Combo (22 episodes in 14 participants) compared to LMix (43 episodes in 20 participants; P = 0.0028), but not significantly different from G + L (28 episodes in 19 participants; P = 0.2523). BC Combo demonstrated superior early PPG control with fewer hypoglycaemic episodes compared to LMix and superior early PPG control compared to separate G + L administrations.<br /> (© 2019 John Wiley & Sons Ltd.)

Details

Language :
English
ISSN :
1463-1326
Volume :
21
Issue :
7
Database :
MEDLINE
Journal :
Diabetes, obesity & metabolism
Publication Type :
Academic Journal
Accession number :
30828929
Full Text :
https://doi.org/10.1111/dom.13685